myprivateMD

Precision Advantage

Beyond Standard Care: Advanced Cardiovascular Risk Assessment and Monitoring

1. Introduction and Context

Robert was a 68-year-old retired engineer who did everything right. He exercised four days a week, maintained a healthy weight, and never smoked. His annual physicals showed an LDL cholesterol of 92 mg/dL, a level his primary care physician praised as "excellent." His stress test at age 65 was normal. Three years later, Robert suffered a massive heart attack that left him with permanent heart damage and a life defined by heart failure medications. His wife asked the question that haunts preventive cardiology: "How does this happen to someone with perfect numbers?"

The answer lies in what those "perfect numbers" never measured. Robert's case is not an outlier. An analysis of 136,905 hospitalizations in the Get With The Guidelines database revealed that **nearly 50% of patients admitted for heart attacks had LDL cholesterol levels below 100 mg/dL**, and approximately 75% had cholesterol levels that would not traditionally indicate elevated cardiovascular risk[1]. The Framingham Heart Study established decades ago that factors beyond total cholesterol and LDL cholesterol must be considered when evaluating coronary artery disease risk[2]. Yet the standard lipid panel, a test rooted in the epidemiological observations of the 1960s and 1970s, remains the default cardiovascular risk assessment tool in most clinical settings.

LDL cholesterol became the standard for practical reasons: it is inexpensive, widely available, and backed by decades of statin trial data showing that lowering it reduces cardiovascular events. For population-level screening, these attributes matter. But population-level tools produce population-level blind spots.

LDL cholesterol measures the **weight** of cholesterol carried within low-density lipoprotein particles. It does not count the particles themselves. It tells clinicians nothing about arterial inflammation, genetic predisposition to accelerated atherosclerosis, or whether calcium has already accumulated in coronary arteries. When standard testing works, it works well. When it fails, it fails silently, and patients like Robert bear the consequences.

Precision cardiovascular medicine represents a fundamental evolution in how we assess and manage cardiovascular risk. Rather than relying on a single biomarker interpreted through population-based guidelines, precision medicine deploys a multi-dimensional assessment integrating advanced biomarkers (apolipoprotein B for atherogenic particle burden, high-sensitivity C-reactive protein for vascular inflammation, lipoprotein(a) for genetically determined risk), anatomical imaging (coronary artery calcium scoring, carotid plaque assessment), and functional testing (cardiopulmonary exercise testing for cardiovascular reserve).

The distinction between "personalized" medicine, which adjusts existing protocols to individual preferences, and "precision" medicine, which tailors diagnosis and treatment to individual biology, is critical. What we describe in this paper is the latter: biological specificity that changes clinical decisions.

The technological and scientific landscape has converged to make this approach feasible at scale. Costs for advanced biomarker testing have decreased substantially. Major guideline bodies have issued consensus statements endorsing many of these tests. The 2024 NLA Expert Consensus established apolipoprotein B as a critical tool for cardiovascular risk assessment[3]. The 2025 ACC Scientific Statement recommended broader use of high-sensitivity CRP screening based on data from over 448,000 adults[4]. Multiple international societies now recommend lipoprotein(a) measurement at least once in every adult's lifetime[5] [6] [7]. Collectively, these represent the current trajectory of evidence-based cardiovascular medicine.

What Makes a Study "Level A" Evidence? (Click to Expand)

Medical evidence is graded on a hierarchy that reflects the strength of the study design. Understanding this hierarchy helps readers evaluate the claims made throughout this paper.

Level A (Strongest): Systematic reviews and meta-analyses of multiple randomized controlled trials (RCTs). These pool data from thousands or tens of thousands of patients across multiple studies, reducing the risk that a single study's quirks drive the conclusion. Examples in this paper: the 593,354-participant ApoB systematic review, the MESA CAC database.

Level B□R (Randomized): Individual randomized controlled trials. Patients are randomly assigned to treatment or placebo, minimizing bias. Examples: CANTOS, COLCOT, and LoDoCo2 trials for inflammation therapy.

Level B□NR (Non-Randomized): Well-designed observational studies, registries, and cohort analyses. These can identify associations but cannot prove causation with the same rigor as RCTs. Example: UK Biobank ApoB discordance analysis.

Level C (Consensus): Expert opinion and consensus statements based on clinical experience when trial data are unavailable. Example: optimal monitoring intervals for serial ApoB measurement.

Throughout this paper, the evidence level supporting each recommendation is noted. Where only Level C evidence exists, that limitation is explicitly acknowledged.

Yet a persistent gap separates what research hospitals and preventive cardiology specialists practice from what most patients receive. Guideline changes typically take 10 to 15 years to reach routine clinical adoption[8]. Many of the tests discussed in this paper carry Class IIa or IIb recommendations, meaning they are "reasonable" or "may be considered" rather than mandated. Insurance coverage remains variable, and patients with access to preventive cardiology programs generally receive more comprehensive risk assessment than those in standard primary care settings.

This white paper serves as a companion to Video 04 in the Prevention Video Series. It expands on the clinical evidence presented in the video and equips readers with the knowledge needed to have informed conversations with their physicians about advanced cardiovascular diagnostics. The evidence hierarchy prioritized throughout includes systematic reviews, large prospective cohort studies, randomized controlled trials, and consensus guidelines from major cardiology organizations. Where evidence gaps exist, they are identified transparently.



Figure 1: The Four Blind Spots of Standard Cholesterol Testing — Standard lipid panels measure only LDL cholesterol weight, missing four critical dimensions of cardiovascular risk: atherogenic particle count (ApoB), vascular inflammation (hs-CRP), genetically determined lipoprotein(a), and coronary artery calcium. Each blind spot has a specific advanced test designed to detect it.

2. Mechanism and Pathophysiology

What You Need to Know

Standard cholesterol tests measure the weight of cholesterol in your blood, but weight alone does not capture the full picture. Cardiovascular disease develops over decades through a process involving cholesterol-carrying particles entering artery walls, triggering inflammation, and gradually forming plaques that can rupture and cause heart attacks. Four critical dimensions of this process are invisible to standard testing: (1) the number of dangerous cholesterol-carrying particles, which matters more than their total cholesterol weight; (2) the level of inflammation in your arteries, which drives plaque instability; (3) a genetically determined risk factor called lipoprotein(a) that affects one in five people and cannot be detected by standard cholesterol panels; and (4)

whether calcium deposits, a sign of established plaque, have already formed in your coronary arteries. Understanding these mechanisms explains why advanced testing exists and what each test is designed to detect.

How Atherosclerosis Develops

Atherosclerosis is not simply a plumbing problem of cholesterol accumulation. It is an inflammatory disease driven by the interplay of cholesterol carrying particles, immune activation, genetic susceptibility, and plaque remodeling over decades.

The process begins at the **endothelium** (the single-cell protective lining of every artery, like the non-stick coating inside a pipe). When this barrier is damaged by hypertension, diabetes, smoking, or metabolic dysfunction, cholesterol-carrying particles penetrate the artery wall. Immune cells follow, attempting to clean up the invading cholesterol — but in doing so, they become overwhelmed and form fatty deposits called **"foam cells"** that are the hallmark of early atherosclerosis.

As these deposits grow, the body walls them off with a **fibrous cap** (a protective layer that separates the dangerous cholesterol core from circulating blood). But ongoing inflammation weakens this cap, releasing destructive enzymes that dissolve the collagen holding it together[9]. When the cap thins sufficiently, plaque rupture exposes the inner core to blood, triggering sudden clot formation — the event that manifests as a heart attack or stroke. Think of it as a thin-walled blister that, when it bursts, triggers a chain reaction that blocks blood flow.



Figure 2: Atherosclerosis Progression Timeline. Illustrates the 40-year development of atherosclerosis from initial endothelial dysfunction through foam cell formation, plaque maturation, fibrous cap thinning, and eventual rupture leading to acute coronary syndrome.

The Role of Inflammation

High-sensitivity C-reactive protein (hs-CRP) serves as a downstream marker of this entire inflammatory process. Produced primarily by the liver in response to inflammatory signals, hs-CRP reflects systemic vascular inflammation and has been shown to predict cardiovascular events independently of cholesterol levels.

The CANTOS trial provided definitive proof of the inflammatory hypothesis by demonstrating that canakinumab, a drug targeting a specific inflammatory pathway, reduced major cardiovascular events without affecting lipid levels[9-1]. In practical terms, this landmark trial proved that inflammation is not just a bystander in heart disease but an active driver that can be treated on its own.



Figure 3: The Inflammatory Pathway — How vascular inflammation drives atherosclerosis progression. High-sensitivity CRP serves as a measurable downstream marker of this process, enabling clinicians to quantify arterial inflammation through a simple blood test.

Why Particle Count Matters More Than Weight

Every atherogenic (plaque-causing) lipoprotein particle carries exactly one molecule of **apolipoprotein B** (ApoB) on its surface. This structural fact makes ApoB a direct count of all dangerous particles in circulation.

LDL cholesterol, by contrast, measures only the mass of cholesterol within LDL particles and misses the cholesterol carried in other particle types. Here is where the critical concept of **discordance** (when two measurements that should track together instead diverge, revealing hidden risk) comes in: when a patient has many small, dense LDL particles, each carrying less cholesterol than a large particle, the total LDL cholesterol may appear normal even though the particle count is dangerously elevated. In other words, the "weight" of cholesterol looks fine, but the "number of delivery trucks" is far too high.



Figure 4: The Discordance Problem — Two patients with identical LDL cholesterol (95 mg/dL) can have very different cardiovascular risk. Patient A has few large particles and a normal ApoB (concordant, truly low risk). Patient B has many small dense particles and a dangerously elevated ApoB (discordant, hidden high risk). This is why measuring ApoB — the particle count — matters.



Figure 5: The Traffic Analogy — Why counting particles (ApoB) matters more than measuring cholesterol weight (LDL-C). In metabolic syndrome, you can have "normal" cholesterol but too many atherogenic particles, just as a highway can be dangerously congested even when each vehicle is small.

This mismatch is most prevalent in patients with insulin resistance, metabolic syndrome, type 2 diabetes, and elevated triglycerides, conditions that shift the LDL particle distribution toward smaller, more numerous, and more dangerous particles[10] [3-1]. In these patients, LDL cholesterol fundamentally underestimates cardiovascular risk, while ApoB reveals the true burden.

The Genetic Wildcard: Lipoprotein(a)

Lipoprotein(a), or Lp(a), adds a genetic dimension to heart disease risk. Structurally similar to LDL, Lp(a) carries an additional protein that mimics a molecule your body normally uses to dissolve blood clots. This molecular mimicry gives Lp(a) a dangerous dual nature: it promotes both plaque formation and clot formation simultaneously.

The LPA gene largely determines circulating Lp(a) levels, with **70 to 90% of an individual's level genetically fixed**[5-1]. Diet, exercise, and most medications do not meaningfully alter Lp(a) concentrations, and statins may actually increase levels slightly. Approximately one in five people worldwide, roughly 1.4 billion individuals, have elevated Lp(a), which doubles or triples the risk of heart attack and aortic valve disease.



Figure 6: The Genetic Wildcard — Lipoprotein(a) is 70-90% genetically determined, invisible to standard cholesterol panels, and affects one in five people worldwide. A single lifetime measurement can reveal a hidden risk factor that no amount of diet or exercise can change.

The Lp(a) Inheritance Pattern Explained (Click to Expand)

Lp(a) levels are primarily controlled by the LPA gene on chromosome 6. Unlike most cardiovascular risk factors, Lp(a) follows a largely **autosomal codominant** inheritance pattern (meaning each parent contributes one gene copy, and both copies influence your final Lp(a) level – similar to how two parents with different eye colors can produce a child with an intermediate eye color).

Key inheritance facts:

- If one parent has elevated Lp(a), each child has approximately a 50% chance of inheriting that elevated level
- If both parents have elevated Lp(a), the probability increases substantially, and levels may be additive
- Lp(a) levels are relatively stable from age 5 onward, meaning a single measurement in adulthood reflects
- lifetime exposure

  The "kringle IV type 2" repeat number in the LPA gene is the primary determinant: fewer repeats produce smaller apo(a) isoforms that are secreted more efficiently, leading to higher Lp(a) levels

Why this matters clinically:

When a patient is found to have elevated Lp(a), cascade family screening (testing parents, siblings, and children) becomes medically indicated because the probability of finding additional affected family members is high. The Case Study in Section 5 ("The Genetic Discovery") illustrates this directly: one woman's Lp(a) of 245 mg/dL led to discovering her brother's elevated level and early coronary atherosclerosis.

Ethnic variation: Lp(a) levels vary significantly by ancestry. Individuals of African descent tend to have higher median Lp(a) levels than those of European or Asian descent, though the risk thresholds for different populations remain an active area of investigation. Current guideline thresholds (above 50 mg/dL) are based predominantly on European-ancestry data.

Even before specific Lp(a)-lowering therapies reach approval (antisense and RNA-based drugs are in late-stage clinical trials), knowing a patient's Lp(a) level fundamentally changes management: it justifies more aggressive LDL targets, intensified inflammatory risk monitoring, cascade family screening, and in some cases access to clinical trials.

What Imaging Reveals

The endpoint of decades of particle accumulation and inflammatory remodeling is visible on imaging. **Coronary artery calcium (CAC) scoring** quantifies calcified plaque in the coronary arteries using a low-dose CT scan with radiation exposure comparable to a mammogram (less than 1 mSv). Calcification represents a late stage of plaque maturation, where the body attempts to stabilize vulnerable plaque by depositing calcium, essentially "reinforcing the bridge."

How CAC Scoring Actually Works (Click to Expand)

Coronary artery calcium scoring uses a non-contrast, ECG-gated CT scan of the heart. The procedure takes approximately 10 to 15 minutes and requires no injections, no fasting, and no special preparation.

The Agatston Method:
The scoring system was developed by Arthur Agatston in 1990 and remains the standard (named after the cardiologist who invented it, this scoring method combines the area and density of calcium deposits into a single number that quantifies total plaque burden). The CT scanner identifies areas of calcification (defined as pixels with density above 130 Hounsfield units) in each of the four main coronary arteries (left main, left anterior descending, left circumflex, and right coronary artery). Each calcified lesion receives a score based on its area and peak density. The total Agatston score is the sum across all coronary arteries.

Score Interpretation:

0 (Zero□□ No detectable coronary calcium. 99% negative predictive value for obstructive coronary disease. "Warranty period" of 3-5 years before repeat testing is considered.

1□99 (Mild□□ Early plaque present. Associated with moderate cardiovascular risk. Typically prompts initiation of preventive therapy (statins, aspirin in selected patients).

100□399 (Moderate): Significant plaque burden. Strong indication for aggressive risk factor modification and pharmacotherapy.

400□ (Extensive): Severe plaque burden. Associated with very high cardiovascular risk. Warrants aggressive multi-modal therapy and close clinical follow-up.

Percentile Scoring:
Because calcium accumulates with age, the raw Agatston score is also interpreted relative to age, sex, and ethnicity using the MESA database. A patient's percentile ranking (e.g., "75th percentile for age and sex") provides context that the raw number alone does not.

Radiation Exposure:
A CAC scan delivers approximately 0.5-1.0 mSv of radiation, comparable to a mammogram and less than a cross-country airplane flight (approximately 0.04 mSv). For context, the average American receives approximately 3.0 mSv of background radiation annually.

Limitations:
CAC scoring detects only calcified plaque. Soft, non-calcified plaque (which may actually be more vulnerable to rupture) is not visualized. This is why a CAC score of zero does not guarantee the complete absence of atherosclerosis, only the absence of calcified disease.

This biological reality has an important clinical paradox: successful statin therapy often **increases** coronary calcium scores because statins promote the conversion of dangerous soft plaque to stable calcified plaque[11]. Think of it this way: soft plaque is like a thin-walled water balloon that can burst at any moment, while calcified plaque is like a hardened scar that is far less likely to rupture. A rising calcium score in a treated patient frequently represents therapeutic success, not disease progression. This is why calcium scoring is best used as a one-time baseline risk assessment rather than a serial monitoring tool.

The Statin Paradox: When a Rising Score Is Good News (Click to Expand)

Many patients who start statin therapy and later undergo a repeat calcium scan are alarmed to find their score has increased. This is one of the most common sources of unnecessary anxiety in cardiovascular prevention. Here is what is actually happening:

Before statins: Your coronary plaques contain a mix of soft, lipid-rich material (vulnerable to rupture) and some calcification. The soft material is the dangerous component — it is what ruptures and causes heart attacks.

After statins: Statins shrink the soft, lipid-rich core and promote calcification of the remaining plaque. The plaque becomes denser and more stable — like converting a fragile eggshell into solid bone. The calcium score goes up because there is more calcified (stable) plaque, but the total amount of dangerous (soft) plaque has decreased.

The bottom line:

- A rising calcium score on statins typically means your medication is working, not failing
- This is why cardiologists do not recommend serial calcium scoring for monitoring — the number goes in the "wrong" direction even when the biology is improving
- Monitoring with ApoB and hs-CRP provides a more accurate picture of whether therapy is reducing your actual risk

What to do if your doctor orders a repeat calcium scan: Ask whether the results will change your management. In most cases, the answer is no — and the anxiety of a higher number is not worth the information gained.



Figure 7: Carotid Plaque Assessment — A radiation-free ultrasound window into atherosclerotic burden. Detecting focal plaque in the carotid arteries is superior to traditional wall-thickness measurements for predicting coronary events, and approximately 30% of patients with normal wall thickness harbor detectable plaque.

Carotid ultrasound offers a complementary and radiation-free window into atherosclerotic burden. Modern assessment focuses on detecting focal atherosclerotic plaque in the carotid arteries rather than measuring vessel wall thickness. Meta-analyses demonstrate that detecting actual plaque is superior to wall-thickness measurements for predicting coronary events, and approximately 30% of patients with normal wall thickness harbor detectable plaque when specifically assessed[12] [13].

The Sleep Connection

Sleep quality is an underrecognized cardiovascular risk factor. Sleep duration follows a U-shaped association with cardiovascular events: both too little and too much sleep increase risk, with **seven to eight hours** associated with the lowest risk[14]. Obstructive sleep apnea independently increases cardiovascular risk through repeated drops in oxygen and chronic stress hormone activation[15]. If you snore loudly, experience daytime fatigue despite adequate sleep hours, or have been told you stop breathing during sleep, discuss a sleep evaluation with your physician.

3. Evidence Base

The clinical value of any diagnostic test rests on the quality of evidence demonstrating that it changes risk assessment and alters clinical decisions. For the advanced diagnostics discussed in this paper, the evidence ranges from robust (Level A, systematic reviews and large randomized trials) to emerging (Level C, consensus-based where trial data are pending).

Apolipoprotein B

ApoB has accumulated the strongest recent evidence for clinical adoption. A systematic review encompassing 593,354 participants found that ApoB outperformed LDL cholesterol in nine out of nine head-to-head comparisons for cardiovascular risk prediction.

The UK Biobank discordance analysis of over 400,000 participants quantified the clinical impact. When ApoB and LDL-C values diverge in a given patient, ApoB more accurately predicts cardiovascular risk[16]. Discordantly high ApoB increased the risk of major cardiovascular events by 11%— roughly one additional heart attack for every nine patients over the study period—while discordantly low ApoB reduced risk by 13%[17] [16-1]. When both ApoB and LDL-C were included in statistical models, ApoB remained a significant predictor while LDL-C did not.

Understanding Hazard Ratios and Confidence Intervals (Click to Expand)

Several studies in this paper report results using **hazard ratios (HR** and **confidence intervals (CI**. Understanding these terms is essential for evaluating the strength of evidence.

Hazard Ratio (HR

A hazard ratio compares the rate of events (such as heart attacks) between two groups over time. An HR of 1.0 means no difference. An HR of 1.11 (as in the ApoB discordance data) means the exposed group experienced 11% more events than the comparison group (roughly one in nine additional heart attacks). An HR of 0.87 means 13% fewer events (roughly one in eight heart attacks prevented).

HR above 1.0 = increased risk (harmful exposure or marker)

HR below 1.0 = reduced risk (protective factor or treatment) **HR □ 1.0** = no difference between groups

95% Confidence Interval (95% CI□□

The confidence interval provides a range within which the true effect likely falls. A 95% CI means that if the study were repeated 100 times, the true value would fall within this range approximately 95 times. The key question: does the confidence interval cross 1.0? If it does, the result is not statistically significant because the true effect could be zero.

Example from this paper:

The COLCOT trial reported a hazard ratio of 0.77 (95% CI: 0.61-0.96) for colchicine versus placebo. This means colchicine reduced the event rate by 23% (roughly one heart attack prevented for every four patients treated), and we can be 95% confident the true reduction is between 4% and 39%. Because the CI does not cross 1.0, the result is statistically significant.

Negative Predictive Value (NPV□□

The CAC "power of zero" finding reports a 99% negative predictive value. This means that among all patients who test negative (CAC = 0), 99% truly do not have obstructive coronary disease (roughly 99 out of 100 patients with a zero score are genuinely protected). NPV is influenced by the prevalence of disease in the tested population, which is why CAC scoring is most informative in intermediate-risk patients.

The NLA 2024 Expert Consensus Statement formalized these findings into clinical practice, identifying specific populations where ApoB testing is most valuable: patients with metabolic syndrome, type 2 diabetes, elevated triglycerides (at or above 150 mg/dL), those on lipid-lowering therapy whose LDL-C is at goal but clinical concern persists, and patients with familial premature cardiovascular disease[3-2]. The NLA statement also issued an explicit call to action: "An urgent need exists to improve access and reimbursement for apoB testing."

High-Sensitivity C-Reactive Protein

hs-CRP has transitioned from an emerging marker to a mainstream risk assessment tool, culminating in the 2025 ACC Scientific Statement on inflammation and cardiovascular disease[4-1].

The concept of **residual inflammatory risk** – hs-CRP at or above 2 mg/L in patients already on statin therapy with LDL below 70 mg/dL – identifies approximately 30% of statin-treated patients who remain at elevated risk despite achieving lipid targets[18]. Nearly one in three patients who achieve "perfect" cholesterol numbers on statins still carry dangerous levels of artery inflammation.

Three landmark trials proved that targeting inflammation reduces events. The CANTOS trial demonstrated that blocking a specific inflammatory pathway reduced major cardiovascular events without affecting lipid levels[9-2]. The COLCOT trial showed that low-dose colchicine achieved a 23% reduction in cardiovascular events after heart attack[19]. The LoDoCo2 trial extended this benefit to patients with stable coronary disease[20].

In statin-treated patients, hs-CRP is a stronger predictor of future events than LDL cholesterol itself[21]. Beyond statins, newer medications including bempedoic acid (a non-statin pill that reduces both cholesterol production and inflammation) and GLP-1 receptor agonists (injectable medications originally developed for diabetes that also reduce weight and inflammation) have demonstrated meaningful hs-CRP reductions[22] [23] [24] [25].

Lipoprotein(a)

Lp(a) evidence has reached a critical mass of guideline endorsement. Affecting approximately 20 to 25% of the global population with elevated levels, Lp(a) confers a **two- to three-fold increase in risk** for heart attack and aortic valve disease – meaning someone with elevated Lp(a) faces two to three times the danger compared to someone with normal levels (roughly the same increase in risk as having diabetes).

The 70 to 90% heritability means that discovering elevated Lp(a) in one patient unlocks the opportunity for **cascade family screening**, potentially identifying at-risk relatives before disease manifests. Multi-society guidelines have converged on recommending testing: the Canadian Cardiovascular Society calls for universal Lp(a) measurement once in a lifetime[7-1], the European Atherosclerosis Society recommends measurement at least once in every person's lifetime[5-2], the NLA 2024 update supports opportunistic or universal screening[6-1], and the 2019
ACC/AHA guidelines identify Lp(a) at or above 50 mg/dL as a risk-enhancing factor[26]. RNA-based therapies are in late-stage clinical trials, though management strategies exist now: more aggressive LDL-C lowering, intensified statin therapy, and for extreme elevations, consideration of lipoprotein apheresis (a procedure that physically removes Lp(a) from the blood).

Coronary Artery Calcium Scoring

CAC scoring draws its strongest evidence from the Multi-Ethnic Study of Atherosclerosis (MESA), a landmark study that has fundamentally shaped how clinicians use imaging for risk stratification.

The **"power of zero"** finding is clinically powerful: if your calcium score is zero, there is a 99% chance you do not have significant blockages[27] [28]. Among patients recommended for statin therapy by guidelines, 41% had CAC scores of zero, potentially allowing them to defer therapy with confidence[29].



Figure 8: The "Power of Zero" — A coronary artery calcium score of zero carries a 99% negative predictive value for obstructive coronary disease. Among patients recommended for statins by guidelines, 41% had CAC scores of zero, enabling informed shared decision-making about therapy initiation.

The **"warranty period"** of a zero calcium score has been estimated at three to five years[30]. CAC scoring is a Class IIa recommendation—meaning "reasonable to perform"—from the ACC/AHA for shared decision-making in borderline and intermediate-risk adults[26-1], and health economic analyses confirm its cost-effectiveness[31].

Evidence Summary Table

Trial / Study	Design	Participants	Key Finding	Evidence Level
ApoB Systematic Review	Meta-analysis	593,354	ApoB outperformed LDL-C in 9/9 comparisons	Level A
UK Biobank Discordance	Prospective cohort	400,000+	Discordant high ApoB increased MACE risk 11%	Level B-NR
CANTOS	Randomized controlled trial	10,061	Anti-inflammatory therapy reduced MACE without lipid change	Level A
COLCOT	Randomized controlled trial	4,745	Colchicine post-MI reduced events by 23%	Level A
LoDoCo2	Randomized controlled trial	5,522	Colchicine in stable CAD reduced events by 31%	Level A
MESA (CAC Zero)	Prospective cohort	6,814	CAC = 0 carried 99% negative predictive value	Level B-NR
MESA (Warranty)	Prospective cohort	6,814	CAC = 0 warranty period: 3-5 years	Level B-NR
Carotid Plaque Metaanalysis	Meta-analysis	Multiple cohorts	Plaque detection superior to CIMT for predicting events	Level A
EAS Lp(a) Consensus	Multi-society statement	N/A	Recommends at least one lifetime Lp(a) measurement	Level C
NLA ApoB Consensus 2024	Expert consensus	N/A	ApoB critical for metabolic syndrome, diabetes, elevated TG	Level C
ACC hs-CRP Statement 2025	Scientific statement	448,000+ reviewed	Recommends broader hs-CRP screening	Level B-NR

Evidence Limitations

This evidence base has limitations that require transparent acknowledgment. Most biomarker data come from observational studies demonstrating association rather than causation from randomized treatment trials. No randomized controlled trial has directly compared ApoB-guided therapy to LDL-C-guided therapy for reducing cardiovascular events.

Optimal monitoring intervals remain consensus-based rather than evidence-derived. The majority of data come from North American and European populations, and Lp(a) thresholds may vary by ethnicity, particularly in individuals of African ancestry who tend to have higher baseline levels with uncertain risk thresholds. This white paper presents the best available evidence while acknowledging these limitations.



Figure 9: Risk Reclassification Through Advanced Testing. Shows how advanced diagnostics (ApoB, hs-CRP, Lp(a), CAC) reclassify 30-40% of intermediate-risk patients, moving some to lower risk categories (CAC=0) and others to higher risk requiring more aggressive therapy.

4. Clinical Application

Translating evidence into clinical practice requires a systematic approach to patient selection, diagnostic sequencing, target setting, and longitudinal monitoring. The goal is not to test every patient for everything, but to deploy the right test for the right patient at the right time, and then to track the right biomarkers to confirm therapy is working.

Advanced Cardiovascular Test Reference

Test	What It Measures	Who Should Consider It	Approximate Cost	Target Values
ApoB	Number of cholesterol-carrying particles in the blood	Metabolic syndrome, diabetes, elevated triglycerides, family history, patients on statins whose LDL-C is at goal	$30-80	Below 90 mg/dL (moderate risk); Below 70 mg/dL (high risk)
hs-CRP	Level of inflammation in the arteries	Statin users with residual risk, patients with unexplained cardiovascular events, anyone with known coronary disease	$15-30	Below 2 mg/L (low risk); Below 1 mg/L (optimal)
Lp(a)	Genetically determined cholesterol risk invisible to standard tests	Everyone (once in a lifetime), especially those with family history of early heart disease	$30-50	Below 30 mg/dL (low risk); Above 50 mg/dL (elevated, warrants action)
CAC Score	Amount of calcium (plaque) already deposited in coronary arteries	Ages 40-75 with borderline or intermediate risk, family history of coronary disease	$99-300	0 (excellent, 99% negative predictive value); 1-99 (mild); 100+ (significant)

Patient Selection

Patient selection begins with the standard 10-year ASCVD risk calculation, which stratifies patients into low (below 5%), borderline (5 to less than 7.5%), intermediate (7.5 to less than 20%), and high (20% or greater) risk categories[32] [26-2].

Advanced biomarker testing adds the greatest value in the **borderline and intermediate risk categories**, where the treatment decision is genuinely uncertain. Specific patient profiles that warrant advanced testing include those with metabolic syndrome or insulin resistance, family history of premature cardiovascular disease, unexpectedly severe disease in young patients, lipid levels that resist treatment, and patients who request objective data before committing to lifelong medication.

In secondary prevention (patients who have already had a cardiovascular event), advanced testing identifies the **mechanism** of residual risk – whether it is driven by excess particles or by inflammation – and guides targeted therapy.

Do I Have Metabolic Syndrome? (Click to Expand)

Metabolic syndrome is mentioned throughout this paper as a key indicator for advanced testing. You may have metabolic syndrome if you meet **three or more** of the following five criteria:

1. **Waist circumference** at or above 40 inches (men) or 35 inches (women)
2. **Triglycerides** at or above 150 mg/dL (or on medication for elevated triglycerides)
3. **HDL cholesterol** below 40 mg/dL (men) or below 50 mg/dL (women)
4. **Blood pressure** at or above 130/85 mmHg (or on blood pressure medication)
5. **Fasting glucose** at or above 100 mg/dL (or on medication for elevated glucose)

Why it matters for advanced testing: Metabolic syndrome shifts your LDL particles toward smaller, denser particles that carry less cholesterol each. This means your LDL cholesterol number can look "normal" while your actual particle count — measured by ApoB — is dangerously high. Metabolic syndrome is the single most common cause of LDL-C/ApoB discordance, which is why the NLA 2024 consensus specifically identifies it as a primary indication for ApoB testing.

How common is it? Approximately one in three American adults meets the criteria for metabolic syndrome. Many do not know it because the individual components are often borderline rather than dramatically abnormal — it is the combination that creates risk.

If you meet three or more of these criteria, ApoB measurement is particularly important for understanding your true cardiovascular risk.

Baseline Diagnostic Approach

The baseline assessment follows a logical sequence. **First**, an advanced lipid panel including ApoB, LDL-C, non-HDL-C, triglycerides, and HDL-C establishes the particle burden and identifies any mismatch between cholesterol content and particle count. **Second**, inflammatory markers, with hs-CRP as the minimum, quantify vascular inflammation. **Third**, Lp(a) measurement, performed once in a lifetime, identifies genetically determined risk that standard testing will never detect. **Fourth**, imaging with coronary artery calcium scoring in intermediate-risk patients provides direct anatomical evidence of disease.

Interpretation requires integrating these data points rather than treating each in isolation: a patient with LDL-C of 95 mg/dL, ApoB of 130 mg/dL, hsCRP of 3.5 mg/L, and a CAC score of 85 is **not** at "borderline" risk regardless of what the risk calculator says. That patient has high particle burden, elevated vascular inflammation, and demonstrated coronary plaque.

Treatment Targets

Treatment targets in precision medicine are tailored to your individual risk level rather than applied as a one-size-fits-all standard. Your doctor may step up treatment in stages, starting conservatively and intensifying based on how your body responds.

For patients at **intermediate risk**, the goals are LDL-C below 100 mg/dL, ApoB below 90 mg/dL, and hs-CRP below 2 mg/L[26-3] [3-3]. For **highrisk** patients, including those with established cardiovascular disease, the targets tighten: LDL-C below 70 mg/dL, ApoB below 70 mg/dL, and hsCRP below 1 to 2 mg/L[33]. Patients at **very high risk**, such as those with extensive coronary calcium (CAC at or above 400) or recurrent cardiovascular events, warrant the most aggressive goals: LDL-C below 55 mg/dL, ApoB below 60 mg/dL, and hs-CRP below 1 mg/L[34].

The treatment approach typically begins with lifestyle changes (healthy dietary patterns, structured exercise, weight management). If targets are not met, your doctor may add a high-intensity statin. From there, additional medications can be layered in: ezetimibe (a cholesterol absorption blocker), **PCSK9 inhibitors** (injectable medications that dramatically lower LDL by helping the liver clear more cholesterol from the blood – PCSK9 is an enzyme that normally destroys LDL receptors, and blocking it allows more receptors to survive and pull cholesterol out of circulation), bempedoic acid (a pill that reduces cholesterol production), or anti-inflammatory therapy such as colchicine. This step-by-step escalation, sometimes called multi-modal therapy (meaning treatment that addresses multiple biological pathways simultaneously), ensures that each patient receives precisely the level of treatment their biology demands.



Figure 10: Treatment Escalation Pathway. Step-by-step progression from lifestyle optimization through high-intensity statins, additional lipid-lowering therapy, anti-inflammatory agents, to combined multi-modal treatment, with decision points at each stage based on biomarker responses.

The Monitoring Revolution

The monitoring revolution represents precision medicine's most meaningful departure from standard care. Standard practice treats patients, rechecks a lipid panel in six to eight weeks, and if LDL-C is "at goal," declares success. Precision monitoring operates at **four levels simultaneously**.

At the **anatomical level**, coronary artery calcium and carotid plaque provide a one-time baseline assessment of disease burden. Imaging is generally not repeated because calcium scores increase with successful statin therapy due to plaque stabilization.

At the **functional level**, **cardiopulmonary exercise testing (CPET** (a comprehensive fitness assessment that measures how well your heart, lungs, and muscles work together during exercise) measures **peak oxygen**

consumption (VO2max (the maximum rate your body can consume oxygen, expressed in milliliters per kilogram per minute – think of it as your cardiovascular system's horsepower), which is the strongest predictor of all-cause mortality in adults over 65. Think of CPET as a "flight test for the cardiovascular system." It is monitored at baseline and annually or with significant clinical change.

At the **inflammatory level**, serial hs-CRP measurement (quarterly to biannually during active management, annually once stable) confirms that vascular inflammation is controlled, with a target below 2 mg/L and ideally below 1 mg/L for high-risk patients. Measurements should be separated by at least three months to distinguish true change from normal fluctuation[35].

At the **particle level**, serial ApoB measurement every three to six months during treatment intensification documents that particle count is falling, confirming therapy is working at the cellular level rather than at the proxy level of cholesterol weight.



Figure 11: Standard Care vs. Precision Monitoring — Standard practice checks LDL cholesterol and declares success. Precision monitoring operates at four levels simultaneously: anatomical (imaging), functional (exercise capacity), inflammatory (hs-CRP), and particle (ApoB), transforming prevention from "treat and hope" to "treat and verify."



Figure 12: Precision Monitoring Framework — Four simultaneous monitoring dimensions: Anatomical (CAC/carotid), Functional (CPET/VO2max), Inflammatory (hs-CRP), and Atherogenic Particles (ApoB), with specific biomarkers, timing, and targets for each level.

The detailed monitoring intervals for each test are consolidated in the Precision Medicine Checklist in Section 7, which patients can print and bring to appointments. This four-level monitoring framework transforms cardiovascular prevention from "treat and hope" to "treat and verify."

5. Case Studies

Three composite clinical scenarios illustrate how precision diagnostics alter the trajectory of cardiovascular risk management.

The Hidden Risk: Metabolic Syndrome with "Normal" Cholesterol

A 48-year-old man with metabolic syndrome presented for cardiovascular risk assessment. His waist circumference was 42 inches, triglycerides 210 mg/dL, and HDL cholesterol 35 mg/dL. His calculated 10-year risk was 6%, placing him in the borderline category. His standard lipid panel showed an LDL cholesterol of 98 mg/dL, a value his previous physician had deemed "at goal."

Advanced testing revealed a starkly different picture. His ApoB was 135 mg/dL, representing significant discordance with his apparently favorable LDL-C and indicating a high number of dangerous particles driven by insulin resistance. His hs-CRP was 3.8 mg/L, reflecting active vascular inflammation. His Lp(a) was 18 mg/dL, reassuringly normal. His coronary artery calcium score was 85, confirming moderate plaque burden and reclassifying him from borderline to high risk.

He was initiated on high-intensity statin therapy with ezetimibe and a GLP-1 receptor agonist for weight management and anti-inflammatory effects, with targets of ApoB below 70 and hs-CRP below 2. At six-month follow-up, his LDL-C had fallen to 62 mg/dL, his ApoB had improved to 72 mg/dL (approaching but not yet at target), his hs-CRP had decreased to 1.8 mg/L, and he had lost 18 pounds. Exercise testing showed a 12% improvement in cardiovascular fitness.

Without ApoB measurement, this patient would have been told his cholesterol was fine. Without CAC scoring, he would have remained classified as borderline risk. Without multi-modal monitoring, there would have been no objective confirmation that therapy was meaningfully reducing his biological burden.

Key Lesson: "Normal" cholesterol can hide dangerous particle counts.

The Genetic Discovery: A Family Mystery Solved

A 35-year-old woman presented with no traditional cardiovascular risk factors but a devastating family history: her father suffered a heart attack at age 42, and her paternal grandfather died of a heart attack at 48. Her calculated 10-year risk was less than 1%, a figure that captures the fundamental limitation of risk calculators in young patients.

Her LDL-C was 128 mg/dL and ApoB 98 mg/dL, both mildly elevated but concordant. Her hs-CRP was an excellent 0.8 mg/L. Her CAC score was zero, expected at her age. But her **Lp(a) was 245 mg/dL**, very high and immediately explanatory. Her family's "premature" heart disease had a genetic cause that standard testing would never have identified.

Despite her low calculated risk, she was treated as high-risk based on her Lp(a), with aggressive LDL-C and ApoB targets set at below 55 mg/dL. Cascade testing was recommended for her siblings. Her brother, age 38, was found to have an Lp(a) of 268 mg/dL and a CAC score of 12, early but definitive evidence of coronary atherosclerosis. Her sister, age 32, had an Lp(a) of 18 mg/dL, having not inherited the pathogenic variant.

One test, performed once, identified the mechanism behind a family's cardiovascular tragedies and enabled prevention in the next generation before disease manifested clinically.

Key Lesson: Family history is often genetic, and genes can be measured.

The Inflammation Phenotype: When "Optimal" Cholesterol Is Not Enough

A 62-year-old man, two years after a heart attack and on maximally tolerated statin and ezetimibe therapy, presented with recurrent chest discomfort despite a negative stress test. His LDL cholesterol was 48 mg/dL and ApoB 62 mg/dL, both at goal. Standard care would have declared his lipid management optimal.

But his hs-CRP remained persistently elevated at 5.2 mg/L despite optimal lipid control — a clear signal of ongoing vascular inflammation. His exercise testing revealed a VO2max of 18 mL/kg/min, below expected for his age and sex, indicating compromised cardiovascular reserve.

His clinical picture was one of **residual inflammatory risk**, the mechanism responsible for a substantial proportion of recurrent events in optimally treated patients. Low-dose colchicine (0.5 mg daily) was added, and he was enrolled in a structured cardiac rehabilitation program. At six-month follow-up, his hs-CRP had decreased to 2.1 mg/L (improved but not yet optimal), VO2max had improved to 22 mL/kg/min, and his chest discomfort had resolved.

This case demonstrates that "optimal" LDL-C does not mean optimal risk reduction, that inflammation requires targeted therapy, and that functional capacity provides independent information that no blood test can replicate.

Key Lesson: Perfect cholesterol does not mean perfect protection.

Themes Across Cases

Four patterns emerge from these composite scenarios. First, standard testing created a false sense of security in every case—Robert's "excellent" LDL, the metabolic syndrome patient's "at goal" numbers, and the post-MI patient's "optimal" lipids all masked active disease. Second, advanced diagnostics identified the specific biological mechanism driving each patient's risk—particle excess, genetic predisposition, or persistent inflammation—enabling targeted rather than generic treatment. Third, the downstream consequences of precision testing extended beyond the individual patient: cascade family screening in the genetic discovery case identified a brother with early coronary atherosclerosis and enabled prevention before a clinical event. Fourth, serial monitoring provided objective confirmation that therapy was working at the biological level, transforming the patient experience from "take this pill and hope for the best" to "here is the proof that your biology is responding." The common thread: measuring what matters changes what happens.



Figure 13: Three Patients, Three Hidden Risks — Side-by-side comparison of three composite case studies showing how standard testing declared each patient safe while advanced diagnostics revealed three distinct hidden mechanisms: particle excess, genetic Lp(a), and residual inflammation. Each required a different targeted intervention.

Five Questions to Ask Your Doctor About Advanced Testing (Click to Expand)

These case studies illustrate why advanced testing matters. If you are considering precision cardiovascular assessment, bring these questions to your next appointment:

1. **"Is my LDL cholesterol telling the full story?"** Ask whether ApoB measurement would add useful information, especially if you have metabolic syndrome, diabetes, elevated triglycerides, or a family history of early heart disease.
2. **"What is my inflammation level?"** Request an hs-CRP test. If you are already on a statin and your hs-CRP remains above 2 mg/L, you may have residual inflammatory risk that requires targeted treatment.
3. **"Should I get my Lp(a) checked?"** This is a once-in-a-lifetime test. If your result is elevated (above 50 mg/dL), your siblings and children should be tested as well.
4. **"Would a coronary calcium score help clarify my risk?"** If your calculated risk is borderline or intermediate, a CAC score can reclassify you up or down and inform whether medication is warranted.
5. **"How will we know if treatment is actually working?"** Ask about a monitoring plan that tracks ApoB, hs-CRP, and functional capacity over time rather than relying solely on LDL cholesterol.

6. Frequently Asked Questions and Common Objections

Many patients encounter advanced cardiovascular diagnostics for the first time with skepticism. The questions that follow address the most common objections, grounded in the evidence presented throughout this paper.

Why Isn't My Regular Doctor Already Doing These Tests?

As discussed in the introduction, guideline adoption typically lags research by over a decade. Insurance barriers deter ordering, and many physicians completed training before these biomarkers were validated.

These tests are not experimental. They are endorsed by major professional societies and used routinely at academic medical centers and preventive cardiology practices. The delay reflects how long evidence takes to reach general practice, not any question about their validity.

What If My Doctor Won't Order These Tests?

If your primary care physician is unfamiliar with or reluctant to order advanced cardiovascular biomarkers, several practical pathways exist. First, you can request a referral to a **preventive cardiologist** — a subspecialist focused specifically on risk assessment and disease prevention rather than procedural intervention. Many academic medical centers and large cardiology groups have dedicated preventive cardiology programs. Second, **concierge medicine and direct-primary-care practices** frequently include advanced biomarker panels as part of their annual assessments, since they operate outside the constraints of insurance-driven visit templates. Third, some commercial laboratories (Quest Diagnostics, LabCorp) offer direct-to-consumer ordering for ApoB, hs-CRP, and Lp(a) in states where this is permitted, though results should be interpreted in consultation with a physician. The goal is not to bypass your doctor but to find a clinical partner equipped to integrate these data into your care.

Is This Just a Way to Sell Unnecessary Services?

The evidence base speaks for itself. Systematic reviews, multi-society consensus guidelines, and statements from the NLA, ACC, AHA, EAS, ESC, and CCS collectively endorse these diagnostics. All tests are available at standard commercial laboratories.

For context, an advanced testing panel costs $500 to $1,000 out-of-pocket in the worst case[36] [37]. The cost comparison table below places this alongside common cardiac procedures for reference. Advanced testing changes clinical management in approximately 30 to 40% of intermediaterisk patients.

Prevention vs. Treatment Cost Comparison

Scenario	Approximate Cost	Notes
Advanced prevention panel (ApoB + hs-CRP + Lp(a) + CAC)	$200-500	One-time comprehensive assessment; Lp(a) and CAC are once-in-alifetime
Annual monitoring (ApoB + hs-CRP + standard lipids)	$100-250	Ongoing precision monitoring during active management
Worst-case panel (all tests, no insurance)	$500-1,000	Maximum out-of-pocket if completely uninsured
Emergency department visit	$3,000+	Single visit, no procedures
Nuclear stress test	$1,500+	Diagnostic only, no treatment
Cardiac catheterization	$15,000+	Invasive diagnostic procedure
Coronary stent placement	$30,000+	Single vessel intervention
Coronary artery bypass surgery	$100,000+	Major open-heart surgery
Heart failure management (annual)	$30,000-50,000+	Medications, hospitalizations, device therapy
Lost wages from cardiac event	Variable	Average 6-12 weeks recovery for MI; longer for CABG

I Have Low LDL-C, So Why Do I Need More Testing?

This objection reflects the central paradox documented in the introduction. Low LDL-C does not ensure a low particle count, does not exclude vascular inflammation, and cannot detect genetic factors like elevated Lp(a). Subclinical coronary plaque may already exist in arteries that appear healthy by every standard measure.

Will This Lead to More Medications?

Testing informs without obligating treatment. Many patients find that objective knowledge of their risk, such as learning they have a CAC score above zero, becomes a powerful motivator for dietary change and exercise adherence. Some findings change management without any medication at all: discovering elevated Lp(a) enables family screening that can save lives.

Precision medicine often means **different** medications, not simply **more** of them. Serial monitoring provides the confidence that therapies are working, which paradoxically improves medication adherence because patients see objective proof that their effort and investment are producing biological change.

What About Cost and Insurance Coverage?

Individual tests are affordable: ApoB ($30-80), hs-CRP ($20-50), Lp(a) ($50-100), and CAC scoring ($99-300)[3-4]. Coverage is improving as major society guidelines strengthen their recommendations, and the NLA 2024 Expert Consensus explicitly calls for improved access and reimbursement for ApoB testing.

Could Test Results Make Me Uninsurable?

Federal law provides meaningful protections. The Genetic Information Nondiscrimination Act (GINA) prohibits the use of genetic information in health insurance and employment decisions[38], and the Affordable Care Act provides pre-existing condition protections. Knowledge of cardiovascular risk does not create the risk — the risk was always present.

Understanding Your GINA Protections in Detail (Click to Expand)

If you are considering Lp(a) testing or other genetic-adjacent cardiovascular diagnostics, understanding your legal protections can reduce anxiety about the process.

What GINA protects:

- Health insurance companies cannot use genetic test results to deny coverage, set premiums, or impose pre-existing condition exclusions
- Employers with 15 or more employees cannot use genetic information in hiring, firing, promotion, or job assignment decisions Health insurers cannot request or require genetic testing

What GINA does NOT protect:

Life insurance — insurers may ask about genetic test results and use them in underwriting decisions
Disability insurance — same exception as life insurance
Long-term care insurance — same exception
Employers with fewer than 15 employees — not covered by GINA's employment provisions **Military personnel** — covered by separate regulations

Practical steps if you have concerns:

1. If you plan to purchase or increase life insurance or disability coverage, consider doing so **before** undergoing Lp(a) or other genetic testing
2. Review your existing policies — once a life insurance policy is in force, results from later testing generally cannot be used to revoke it
3. Note that Lp(a) testing measures a protein level, not a gene directly — some legal experts argue this falls outside GINA's strict definition of "genetic test," though the distinction has not been fully tested in courts
4. The ACA's pre-existing condition protections apply regardless of genetic status for health insurance purchased through the marketplace

The perspective: The cardiovascular risk from undetected elevated Lp(a) is far greater than the insurance risk from knowing about it. Most patients who learn their Lp(a) status find that the knowledge enables better medical decisions without meaningful insurance consequences.

Can Lifestyle Changes Affect These Biomarkers?

The role of lifestyle is substantial. hs-CRP is highly responsive: Mediterranean-style dietary patterns, weight loss, and regular exercise (150 minutes per week of moderate activity) all produce meaningful reductions[39] [40] [41]. It is worth noting that cardiovascular benefits from dietary patterns come from whole foods – olive oil, nuts, fish, vegetables, and whole grains – rather than from alcohol or supplements. The VITAL trial of 25,871 participants showed that omega-3 and vitamin D supplements did not reduce major cardiovascular events[42], underscoring that whole-food patterns deliver benefits supplements cannot replicate.

ApoB is responsive to low-carbohydrate diets in metabolic syndrome patients and to weight loss. **Lp(a), however, is not meaningfully responsive to any lifestyle intervention**, reinforcing why genetic risk requires pharmacologic strategies. VO2max is highly responsive to structured exercise training, making it both a prognostic marker and a therapeutic target.

The Mediterranean Plate at a Glance (Click to Expand)

The evidence consistently points to whole-food Mediterranean-style dietary patterns as the most effective nutritional strategy for reducing vascular inflammation and improving biomarker profiles. Here is what a typical day looks like:

Build every meal around:

- Extra virgin olive oil (primary cooking fat)
- Vegetables and leafy greens (at least 5 servings daily)
- Whole grains (oats, whole wheat bread, brown rice)
- Legumes (beans, lentils, chickpeas)

Include regularly:

- Fatty fish 2-3 times per week (salmon, sardines, mackerel)
- Nuts and seeds (a small handful daily)
- Fresh fruit (2-3 servings daily)

Limit or avoid:

- Processed meats (bacon, sausage, deli meats)
- Refined sugars and white flour products
- Ultra-processed packaged foods
- Alcohol (the WHO position is that no level is safe for health[43] [44]; while older epidemiological data suggested modest cardiovascular benefit from light drinking, more recent analyses controlling for abstainer bias have weakened that association — discuss with your physician if you have questions)

Key principle: Cardiovascular benefits come from the overall dietary pattern, not individual supplements. The VITAL trial (25,871 participants) showed omega-3 and vitamin D supplements did not reduce major cardiovascular events [42-1].

Can the Calcium Score Be Used for Monitoring?

Serial calcium scoring is generally not recommended because calcium increases with successful statin therapy as part of plaque stabilization. Calcium scoring is a **baseline risk stratification** tool. Monitoring uses different instruments: ApoB tracks particle reduction, hs-CRP tracks inflammatory control, and exercise testing tracks functional capacity. Different tools serve different purposes.

7. Summary and Next Steps

Five Things to Remember:

1. **Standard testing misses half the risk.** Nearly 50% of heart attack patients have LDL cholesterol levels that would not have triggered concern, because standard panels cannot measure particle count, inflammation, or genetic predisposition.

2. **Advanced tests are guideline-supported.** ApoB, hs-CRP, Lp(a), and coronary artery calcium scoring are endorsed by the NLA, ACC, AHA, EAS, and multiple international societies – these are not experimental or fringe recommendations.

3. **Treatment is tailored to your biology.** Precision medicine matches therapy to the specific mechanism driving your risk, whether that is excess particles, vascular inflammation, genetic factors, or a combination, rather than applying a one-size-fits-all protocol.

4. **Monitoring shows if it is working.** Serial measurement of ApoB, hs-CRP, and functional capacity provides objective proof that treatment is producing biological change, transforming prevention from "treat and hope" to "treat and verify."

5. **This is precision medicine, not guesswork.** The philosophy is simple: measure before treating, personalize based on individual biology, monitor to verify success, and prevent rather than react.

Your Precision Medicine Checklist (Click to Expand)

Use this checklist to track your advanced cardiovascular assessment. Print this page and bring it to your physician appointments.

One-Time Assessments (do once, know forever):

- ☐ Lp(a) measurement — reveals genetically determined risk invisible to standard testing. Recheck only if initial result is near the 50 mg/dL threshold or if the assay method changes.
- ☐ Coronary artery calcium score — if you are age 40-75 with borderline or intermediate risk. Do not repeat: a rising score on statins reflects plaque stabilization, not failure.
- ☐ Carotid ultrasound — radiation-free alternative if CAC is unavailable or complementary data is needed
- ☐ If Lp(a) is elevated: cascade family screening for parents, siblings, and children

Baseline Panel (starting point for precision monitoring):

- ☐ ApoB level — your atherogenic particle count
- ☐ hs-CRP level — your vascular inflammation marker (defer testing during acute illness; separate measurements by at least 3 months)
- ☐ Standard lipid panel (LDL-C, HDL-C, triglycerides, non-HDL-C) — interpret alongside ApoB for discordance
- ☐ Cardiopulmonary exercise test (VO2max) — your cardiovascular fitness benchmark; most informative in patients over 65

Ongoing Monitoring — Active Management Phase:

- ☐ ApoB every 3-6 months until at target; recheck 6-8 weeks after any medication change
- ☐ hs-CRP every 3-6 months until below 2 mg/L (ideally below 1 mg/L)
- ☐ Standard lipids every 3-6 months
- ☐ VO2max annually

Ongoing Monitoring — Stable Maintenance Phase:

- ☐ ApoB every 6-12 months
- ☐ hs-CRP annually
- ☐ Standard lipids every 6-12 months
- ☐ VO2max annually

Know Your Targets:

- ApoB: below 90 mg/dL (moderate risk), below 70 mg/dL (high risk), below 60 mg/dL (very high risk)
- hs-CRP: below 2 mg/L (acceptable), below 1 mg/L (optimal for high-risk patients)
- LDL-C: below 100 mg/dL (moderate risk), below 70 mg/dL (high risk), below 55 mg/dL (very high risk)

For Patients

Request an advanced lipid panel that includes ApoB at your next appointment. Ask about hs-CRP measurement, especially if you are already on statin therapy. Get Lp(a) tested once for lifetime knowledge. Consider coronary artery calcium scoring if you are at intermediate risk or have a family history of premature cardiovascular disease. Discuss a precision monitoring strategy with a physician who is equipped to interpret these results and adjust management accordingly.

For Caregivers and Family Members

If you are reading this on behalf of a parent, spouse, or loved one, your role in precision cardiovascular prevention is substantial. Many patients in the target demographic will benefit from a family member who understands what these tests mean and can advocate for comprehensive assessment.

Be the informed advocate. Attend cardiology appointments together. When results come back, help interpret them using the targets listed in this paper. If your loved one's physician checks only LDL cholesterol without ApoB, ask why. You are not being difficult; you are being thorough.

Understand the genetic implications. If a family member is found to have elevated Lp(a), this affects the entire family. Cascade screening—testing parents, siblings, and children—can identify at-risk relatives before disease manifests. The genetic discovery case study in Section 5 illustrates how one woman's Lp(a) result led to early detection of coronary atherosclerosis in her brother.

Track the numbers together. Help maintain a simple log of ApoB, hs-CRP, and LDL-C results at each visit. Seeing the trend over time provides motivation during what can feel like an abstract process. When your loved one can see their inflammation marker falling or their particle count dropping, adherence to medication and lifestyle changes improves.

Support lifestyle changes as a partner. Cook Mediterranean-style meals together. Join walking or exercise programs together. These changes are easier to sustain when they become household habits rather than individual burdens.

Watch for signs of discouragement. Cardiovascular prevention is a long-term commitment, and it is common for patients to question whether their effort is worthwhile, especially when they "feel fine." Precision monitoring provides the answer: objective biomarker improvement is proof that effort is producing biological change.

For Clinicians

The evidence supports integrating ApoB into routine lipid assessment (especially for metabolic syndrome, diabetes, and elevated triglycerides), implementing the ACC 2025 hs-CRP screening recommendations, adopting once-in-a-lifetime Lp(a) testing, and using CAC scoring for shared decision-making in borderline and intermediate-risk patients. Serial monitoring protocols tracking atherogenic particles, inflammation, and functional capacity can further refine management in high-risk patients.

Conflicts of Interest: None declared.
Funding: No external funding was received for this white paper.
Disclaimer: This document is intended for educational purposes and does not constitute individualized medical advice. Readers should consult qualified healthcare providers for personal medical decisions.

8. Glossary of Terms and Abbreviations

ACC (American College of Cardiology): Major U.S. professional organization for cardiovascular specialists. Issues clinical practice guidelines and scientific statements that shape cardiovascular care nationwide.

AHA (American Heart Association): National voluntary health organization focused on cardiovascular disease and stroke. Co-develops clinical guidelines with the ACC and funds cardiovascular research.

ApoB (Apolipoprotein B□□ The protein that wraps around every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)). Because each particle carries exactly one ApoB molecule, measuring ApoB provides a direct count of dangerous particles in circulation. More informative than LDL-C in patients with metabolic syndrome, diabetes, or elevated triglycerides. Target: below 90 mg/dL (moderate risk), below 70 mg/dL (high risk), below 60 mg/dL (very high risk).

ASCVD (Atherosclerotic Cardiovascular Disease): Umbrella term encompassing coronary artery disease, stroke, and peripheral artery disease caused by atherosclerosis. The 10-year ASCVD risk score is the standard tool for estimating cardiovascular event probability.

CAC (Coronary Artery Calcium): Calcified plaque deposits in the coronary arteries, quantified by a low-dose CT scan using the Agatston scoring method. A score of zero carries 99% negative predictive value for obstructive coronary disease. See Section 2 callout for detailed scoring interpretation.

CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study): Landmark randomized controlled trial (n=10,061) that proved the inflammatory hypothesis of atherosclerosis by showing that canakinumab (an IL-1 beta inhibitor) reduced cardiovascular events without affecting lipid levels.

CCS (Canadian Cardiovascular Society): Canadian professional organization that issues clinical practice guidelines, including the recommendation for universal once-in-a-lifetime Lp(a) measurement.

CI (Confidence Interval): Statistical range within which the true effect likely falls. A 95% CI means that if the study were repeated 100 times, the true value would fall within this range approximately 95 times. See Section 3 callout for detailed explanation.

CIMT (Carotid Intima-Media Thickness): Ultrasound measurement of the thickness of the inner two layers of the carotid artery wall. Largely superseded by direct plaque detection, which has superior predictive value for coronary events.

COLCOT (Colchicine Cardiovascular Outcomes Trial): Randomized controlled trial (n=4,745) demonstrating that low-dose colchicine (0.5 mg daily) reduced cardiovascular events by 23% after myocardial infarction.

CPET (Cardiopulmonary Exercise Testing): A comprehensive assessment of cardiovascular, pulmonary, and metabolic function during exercise. Measures peak oxygen consumption (VO2max), which is the strongest predictor of all-cause mortality in adults over 65.

EAS (European Atherosclerosis Society): European scientific society focused on atherosclerosis research and clinical practice. Issued the 2022 consensus statement on lipoprotein(a).

ESC (European Society of Cardiology): Major European professional organization that publishes clinical practice guidelines for cardiovascular disease management, including lipid management targets.

GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist): Class of medications (including semaglutide and liraglutide) originally developed for diabetes that have demonstrated cardiovascular benefits including weight loss, anti-inflammatory effects (hs-CRP reduction), and reduced cardiovascular events.

HDL-C (High-Density Lipoprotein Cholesterol): Often called "good cholesterol." HDL particles transport cholesterol away from arteries back to the liver for disposal. Low HDL-C (below 40 mg/dL in men, below 50 mg/dL in women) is a cardiovascular risk factor.

HR (Hazard Ratio): Statistical measure comparing the rate of events between two groups over time. HR above 1.0 indicates increased risk; HR below 1.0 indicates reduced risk. See Section 3 callout for detailed explanation.

hs-CRP (High-Sensitivity C-Reactive Protein): An acute-phase protein produced by the liver in response to inflammatory signals. The highsensitivity assay detects low-grade vascular inflammation relevant to atherosclerosis. Target: below 2 mg/L (low risk), below 1 mg/L (optimal for high-risk patients).

IDL (Intermediate-Density Lipoprotein): A transitional lipoprotein particle between VLDL and LDL in the metabolic pathway. Carries one ApoB molecule and is included in the atherogenic particle count.

IL-1B (Interleukin-1 Beta): A pro-inflammatory cytokine (signaling molecule) that amplifies the inflammatory cascade within atherosclerotic plaques. The CANTOS trial targeted this molecule with canakinumab.

IL-6 (Interleukin-6): A pro-inflammatory cytokine that signals the liver to produce CRP. Serves as an upstream marker of inflammation and may provide additional risk stratification beyond hs-CRP.

LDL-C (Low-Density Lipoprotein Cholesterol): The mass of cholesterol carried within LDL particles. The standard measure of cardiovascular risk for decades, but limited by its inability to count particles directly. May underestimate risk when particles are small and dense.

LoDoCo2 (Low-Dose Colchicine 2□□ Randomized controlled trial (n=5,522) demonstrating that colchicine reduced cardiovascular events by 31% in patients with stable chronic coronary disease.

Lp(a) (Lipoprotein(a)): A genetically determined lipoprotein particle structurally similar to LDL but carrying an additional apolipoprotein(a) protein with kringle domains. Promotes both plaque formation and clot formation. Levels are 70-90% genetically fixed and unresponsive to lifestyle changes. Elevated in approximately 20% of the global population. Threshold: above 50 mg/dL is considered elevated.

MESA (Multi-Ethnic Study of Atherosclerosis): Landmark prospective cohort study (n=6,814) that established the clinical utility of coronary artery calcium scoring across diverse ethnic groups and provided the foundation for CAC-based risk stratification.

MPO (Myeloperoxidase): An enzyme released by activated white blood cells that directly damages the fibrous cap of atherosclerotic plaques, promoting plaque vulnerability and rupture.

NLA (National Lipid Association): U.S. professional organization focused on lipid management. Issued the 2024 Expert Consensus supporting ApoB as a critical clinical tool.

NRI (Net Reclassification Improvement): Statistical measure quantifying how much a new biomarker improves risk classification compared to existing models (calculated by counting how many patients move to more accurate risk categories when the new test is added). Used to evaluate whether adding ApoB, hs-CRP, or CAC to standard risk calculators meaningfully changes patient management.

NPV (Negative Predictive Value): The probability that a person with a negative test result truly does not have the disease. The CAC score of zero has a 99% NPV for obstructive coronary disease.

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Injectable medications (evolocumab, alirocumab) that dramatically lower LDL-C by 50-60% by preventing the degradation of LDL receptors on liver cells, enabling the liver to clear more LDL from the blood.

QALY (Quality-Adjusted Life Year): Health economic measure combining quantity and quality of life (one QALY equals one year of life in perfect health, while a year with moderate disability might equal 0.7 QALYs). Used in cost-effectiveness analyses to determine whether a medical intervention provides good value.

VLDL (Very Low-Density Lipoprotein): A large lipoprotein particle produced by the liver that carries triglycerides and cholesterol. Carries one ApoB molecule. Elevated in metabolic syndrome, diabetes, and high-triglyceride states.

VO2max (Maximum Oxygen Consumption): The maximum rate at which the body can consume oxygen during exercise, measured during cardiopulmonary exercise testing. Expressed in mL/kg/min. The strongest predictor of all-cause mortality in adults over 65. Highly responsive to structured exercise training.

Kayur V. Patel, MD
KayurVPatel@MyPrivate.MD

9. References

1. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009 Jan;157(1):111-117.e2. PMID: 19081406. https://pubmed.ncbi.nlm.nih.gov/19081406/ DOI: https://doi.org/10.1016/j.ahj.2008.08.010
2. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977 May;55(5):767-772. PMID: 191215. https://pubmed.ncbi.nlm.nih.gov/191215/
3. Domanski MJ, Tian X, Wu CO, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct;18(5):e742-e760. PMID: 39256087. https://pubmed.ncbi.nlm.nih.gov/39256087/ DOI: https://doi.org/10.1016/j.jacl.2024.08.013
4. Mensah GA, Roth GA, Fuster V. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025 Sep 29. PMID: 41020749. https://pubmed.ncbi.nlm.nih.gov/41020749/ DOI: https://doi.org/10.1016/j.jacc.2025.08.047
5. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 21;43(39):3925-3946. PMID: 36036785. https://pubmed.ncbi.nlm.nih.gov/36036785/ DOI: https://doi.org/10.1093/eurheartj/ehac361
6. Tsimikas S, Karwatowska-Prokopczuk E, Moriarty PM, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun;18(3):e373-e395. PMID: 38565461. https://pubmed.ncbi.nlm.nih.gov/38565461/ DOI: https://doi.org/10.1016/j.jacl.2024.03.001
7. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150. PMID: 33781847. https://pubmed.ncbi.nlm.nih.gov/33781847/ DOI: https://doi.org/10.1016/j.cjca.2021.03.016
8. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011 Dec;104(12):510520. PMID: 22179294. https://pubmed.ncbi.nlm.nih.gov/22179294/ DOI: https://doi.org/10.1258/jrsm.2011.110180
9. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. PMID: 28845751. https://pubmed.ncbi.nlm.nih.gov/28845751/ DOI: https://doi.org/10.1056/NEJMoa1707914
10. Park HE, Choi SY, Kim MK, et al. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Endocrinol Metab (Seoul). 2015 Jun;30(2):208-215. PMID: 26194080. https://pubmed.ncbi.nlm.nih.gov/26194080/ DOI: https://doi.org/10.3803/EnM.2015.30.2.208
11. Maron DJ, Budoff MJ, Sky JC, Bommer WJ, Epstein SD. Coronary Artery Calcium Staging to Guide Preventive Interventions: A Proposal and Call to Action. JACC Adv. 2024 Nov;3(11):101287. PMID: 39385944. https://pubmed.ncbi.nlm.nih.gov/39385944/ DOI: https://doi.org/10.1016/j.jacadv.2024.101287
12. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a metaanalysis. Atherosclerosis. 2012 Jan;220(1):128-133. PMID: 21764060. https://pubmed.ncbi.nlm.nih.gov/21764060/

DOI: https://doi.org/10.1016/j.atherosclerosis.2011.06.044

13. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010 Dec 21;122(25):e584-e636. PMID: 21098428. https://pubmed.ncbi.nlm.nih.gov/21098428/

    DOI: https://doi.org/10.1161/CIR.0b013e3182051b4c

14. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011 Jun;32(12):1484-1492. PMID: 21300732. https://pubmed.ncbi.nlm.nih.gov/21300732/

    DOI: https://doi.org/10.1093/eurheartj/ehr007

15. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017 Feb 21;69(7):841-858. PMID: 28209226. https://pubmed.ncbi.nlm.nih.gov/28209226/ DOI: https://doi.org/10.1016/j.jacc.2016.11.069

16. Thanassoulis G, Williams K, Ye K, et al. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. Eur J Prev Cardiol. 2025 Jan. PMID: 40887080. https://pubmed.ncbi.nlm.nih.gov/40887080/ DOI: https://doi.org/10.1093/eurjpc/zwaf554

17. Richardson TG, Wang Q, Sanderson E, et al. Impact of LDL-C and Apolipoprotein B Level Discordance and associated Lipoprotein Particle Alterations on Cardiovascular Outcomes in a large primary prevention population. Eur J Prev Cardiol. 2025 Jan. PMID: 41284723. https://pubmed.ncbi.nlm.nih.gov/41284723/ DOI: https://doi.org/10.1093/eurjpc/zwaf750

18. Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol. 2018 Dec 25;72(25):3320-3331. PMID: 30415883. https://pubmed.ncbi.nlm.nih.gov/30415883/ DOI: https://doi.org/10.1016/j.jacc.2018.06.082

19. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. PMID: 31733140. https://pubmed.ncbi.nlm.nih.gov/31733140/ DOI: https://doi.org/10.1056/NEJMoa1912388

20. Nidorf SM, Fiolet AT, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. PMID: 32865380.

    https://pubmed.ncbi.nlm.nih.gov/32865380/ DOI: https://doi.org/10.1056/NEJMoa2021372

21. Nissen SE, Menon V, Nicholls SJ, et al. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2024 Jan 2;149(3):173-183. PMID: 37929602. https://pubmed.ncbi.nlm.nih.gov/37929602/ DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.066213

22. Ray KK, Wright RS, Kallend D, et al. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. Atherosclerosis. 2023 Jun;373:1-8. PMID: 37075696. https://pubmed.ncbi.nlm.nih.gov/37075696/ DOI: https://doi.org/10.1016/j.atherosclerosis.2023.03.020

23. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-2207. PMID: 18997196. https://pubmed.ncbi.nlm.nih.gov/18997196/ DOI: https://doi.org/10.1056/NEJMoa0807646

24. Marso SP, Zinman B, Poulter NR, et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022 Sep 2;21(1):168. PMID: 36056351. https://pubmed.ncbi.nlm.nih.gov/36056351/

DOI: https://doi.org/10.1186/s12933-022-01585-7

25. Kosiborod MN, Petrie MC, Borlaug BA, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. eClinicalMedicine. 2023 Jan;55:101737. PMID: 36467859. https://pubmed.ncbi.nlm.nih.gov/36467859/ DOI: https://doi.org/10.1016/j.eclinm.2022.101737
26. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232. PMID: 30894318. https://pubmed.ncbi.nlm.nih.gov/30894318/ DOI: https://doi.org/10.1016/j.jacc.2019.03.010
27. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016 Mar 1;133(9):849-858. PMID: 26801055. https://pubmed.ncbi.nlm.nih.gov/26801055/
DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.018524
28. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. 2009 Jun;2(6):675-688. PMID: 19520336. https://pubmed.ncbi.nlm.nih.gov/19520336/ DOI: https://doi.org/10.1016/j.jcmg.2008.12.031
29. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015 Oct 13;66(15):1657-1668. PMID: 26449135. https://pubmed.ncbi.nlm.nih.gov/26449135/ DOI: https://doi.org/10.1016/j.jacc.2015.08.031
30. Miedema MD, Dardari ZA, Nasir K, et al. Warranty Period of a Calcium Score of Zero: Comprehensive Analysis From MESA. JACC Cardiovasc Imaging. 2021 May;14(5):990-1002. PMID: 33129734. https://pubmed.ncbi.nlm.nih.gov/33129734/ DOI: https://doi.org/10.1016/j.jcmg.2020.06.048
31. Mortensen MB, Dzaye O, Bøtker HE, et al. Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis. JACC Adv. 2024 Apr;3(6):100886. PMID: 38939688. https://pubmed.ncbi.nlm.nih.gov/38939688/ DOI: https://doi.org/10.1016/j.jacadv.2024.100886
32. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-S73. PMID: 24222018. https://pubmed.ncbi.nlm.nih.gov/24222018/ DOI: https://doi.org/10.1161/01.cir.0000437741.48606.98
33. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. PMID: 30879355. https://pubmed.ncbi.nlm.nih.gov/30879355/ DOI: https://doi.org/10.1161/CIR.0000000000000678
34. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. PMID: 31504418. https://pubmed.ncbi.nlm.nih.gov/31504418/ DOI: https://doi.org/10.1093/eurheartj/ehz455
35. Silva D, de Lacerda AP. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Rev Port Cardiol. 2012 Nov;31(11):733-745. PMID: 23046630. https://pubmed.ncbi.nlm.nih.gov/23046630/ DOI: https://doi.org/10.1016/j.repc.2012.02.018

36. Empirical Health. ApoB is not usually covered by Medicare or insurance, but can be cheap. 2024. Available at: https://www.empirical.health/blog/medicare-apob-test/

37. BlueRipple Health. ApoB Test: How to Get Tested, Costs, and What Your Results Mean. 2024. Available at: https://blueripple.com/apob/apob-test/

38. National Human Genome Research Institute. Genetic Information Nondiscrimination Act (GINA). 2024. Available at: https://www.genome.gov/about-genomics/policyissues/Genetic-Discrimination

39. Casas R, Sacanella E, Urpi-Sarda M, et al. The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. PLoS One. 2014 Jun 12;9(6):e100084. PMID: 24925270. https://pubmed.ncbi.nlm.nih.gov/24925270/ DOI: https://doi.org/10.1371/journal.pone.0100084

40. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med. 2007 Jan 8;167(1):31-39. PMID: 17210875. https://pubmed.ncbi.nlm.nih.gov/17210875/ DOI: https://doi.org/10.1001/archinte.167.1.31

41. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med. 2000 Jan;21(1):21-24. PMID: 10683094. https://pubmed.ncbi.nlm.nih.gov/10683094/ DOI: https://doi.org/10.1055/s-2000-8852

42. Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019 Jan 3;380(1):23-32. PMID: 30415637. https://pubmed.ncbi.nlm.nih.gov/30415637/ DOI: https://doi.org/10.1056/NEJMoa1811403

43. World Health Organization. No level of alcohol consumption is safe for our health. 2023. Available at: https://www.who.int/europe/news/item/04-01-2023-no-level-ofalcohol-consumption-is-safe-for-our-health

44. International Agency for Research on Cancer. Alcohol and cancer. 2023. Available at: https://www.iarc.who.int/wpcontent/uploads/2021/07/IARC_Evidence_Summary_Brief_2.pdf